BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) announced today the results of its Phase II clinical trial evaluating the safety and wound-healing efficacy of RGN-137 for the treatment of patients with venous stasis ulcers. RGN-137 is a topical gel formulation of thymosin beta 4 peptide (Tß4). The drug candidate was found to be safe and well-tolerated at all three dose levels, with no dose-limiting or drug-related adverse events, which was the primary objective of the trial. Like the previously reported Phase II pressure ulcer trial, the mid-dose level of RGN-137 appeared to be the most active of the three doses and induce more rapid initiation of wound healing compared to placebo.
